Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LESS-AD trial of levetiracetam for seizure prevention in adults with Down syndrome and symptomatic Alzheimer's disease
2024-516148-24-00Phase 3Authorised
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epilepsy, Alzheimer's disease (AD) and Down syndrome comparing Levetiracetam with Placebo (2 arms). Primary endpoint: No bilateral tonic-clonic epileptic seizure during study. Planned start May 2025; status: authorised.
02
Drugs
levetiracetam
03
Conditions
epilepsyAlzheimer's disease (AD)Down syndrome
Beyond the preview
Go deeper on 2024-516148-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516148-24-00.